Acumen Sets November 2026 ALTITUDE-AD Readout With $78.6M Cash Into Early 2027
ABOS sits 35% above its 52-week low of $1.5.
Summary
Acumen reported a $25.4 million Q3 net loss and $78.6 million in cash lasting into early 2027, and said ALTITUDE-AD Phase 2 topline results are now expected in November 2026.
Key Events · Earnings and Guidance · ABOS
-
ALTITUDE-AD Readout Set for November 2026
Acumen now expects topline results from the 542-participant Phase 2 study of sabirnetug in early Alzheimer's disease in November 2026, including the iADRS primary endpoint, CDR-SB, ARIA rates and biomarkers.
-
Cash Falls to $78.6M, Runway Into Early 2027
Cash, cash equivalents and marketable securities were $78.6 million at September 30, 2026, down from $110.2 million at June 30, 2026 — roughly a two-quarter runway that ends around the same time as the data readout.
-
Q3 Loss Narrows on Lower R&D
R&D expense was $21.1 million versus $22.0 million a year earlier and G&A was $4.7 million versus $4.5 million, producing a $25.4 million net loss compared with $26.5 million in Q3 2025.
-
EBD Lead Candidate IND Targeted Mid-2027
The Enhanced Brain Delivery program's lead clinical candidate IND filing is targeted for mid-2027, with non-human primate data showing 14-40x higher brain levels than native antibodies.
Analysis · ABOS · Life Sciences
The quarter itself is unremarkable — loss from operations of $25.8 million was slightly better than a year ago. What matters is the calendar: the Phase 2 ALTITUDE-AD topline readout is now pinned to November 2026, weeks away, and it is the single event that decides whether sabirnetug is a viable Alzheimer's asset. Against that, cash fell to $78.6 million from $110.2 million at June 30 and covers operations only into early 2027 — so the company will likely need to raise money around the same time the data lands. A good readout makes financing cheap; a bad one makes the runway the story.
How filings like this one have moved
In the 30 days to Oct 26, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABOS was trading at $2.02 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $143.2M. The 52-week trading range was $1.50 to $3.60. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.